Q3 2020 Earnings Forecast for Kura Oncology Inc Issued By Oppenheimer (NASDAQ:KURA)

Share on StockTwits

Kura Oncology Inc (NASDAQ:KURA) – Equities research analysts at Oppenheimer issued their Q3 2020 earnings per share (EPS) estimates for Kura Oncology in a note issued to investors on Wednesday, November 6th. Oppenheimer analyst J. Olson forecasts that the company will post earnings per share of ($0.41) for the quarter. Oppenheimer also issued estimates for Kura Oncology’s FY2023 earnings at $1.22 EPS.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03.

Several other research analysts have also commented on KURA. BidaskClub upgraded shares of Kura Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Wednesday. Wedbush reiterated a “positive” rating on shares of Kura Oncology in a research note on Wednesday, September 4th. JMP Securities reiterated a “market outperform” rating and set a $22.00 price objective on shares of Kura Oncology in a research note on Thursday, September 5th. Finally, Deutsche Bank started coverage on shares of Kura Oncology in a research note on Thursday, July 18th. They set a “buy” rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. Kura Oncology has a consensus rating of “Buy” and a consensus price target of $26.11.

NASDAQ KURA opened at $15.53 on Friday. The company has a quick ratio of 23.50, a current ratio of 23.50 and a debt-to-equity ratio of 0.03. The firm has a market cap of $672.35 million, a PE ratio of -9.03 and a beta of 2.57. The company has a 50 day moving average price of $14.92 and a 200 day moving average price of $16.88. Kura Oncology has a 52 week low of $11.01 and a 52 week high of $21.42.

A number of institutional investors have recently modified their holdings of the business. Eagle Asset Management Inc. increased its stake in Kura Oncology by 1.6% during the 3rd quarter. Eagle Asset Management Inc. now owns 2,075,747 shares of the company’s stock valued at $31,489,000 after purchasing an additional 31,878 shares in the last quarter. Alps Advisors Inc. increased its stake in Kura Oncology by 12.7% during the 3rd quarter. Alps Advisors Inc. now owns 90,112 shares of the company’s stock valued at $1,367,000 after purchasing an additional 10,184 shares in the last quarter. SG Americas Securities LLC increased its stake in Kura Oncology by 1,393.4% during the 3rd quarter. SG Americas Securities LLC now owns 103,838 shares of the company’s stock valued at $1,575,000 after purchasing an additional 96,885 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Kura Oncology during the 3rd quarter valued at approximately $114,000. Finally, California Public Employees Retirement System increased its stake in Kura Oncology by 46.4% during the 3rd quarter. California Public Employees Retirement System now owns 45,954 shares of the company’s stock valued at $697,000 after purchasing an additional 14,554 shares in the last quarter. Institutional investors and hedge funds own 84.97% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: Market Capitalization – What it Means for Investors

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.